Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy.

This document explores the effectiveness of venetoclax-combination regimens for treating relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Myeloid malignancies, such as TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), have historically had poor treatment responses and survival rates. While hypomethylating agents (HMAs) and venetoclax combination therapy have been used, outcomes remain suboptimal. The study focuses on patients with AML who received venetoclax-combination therapy after treatment with azacitidine (AZA) and magrolimab, finding that a significant number achieved complete remission or partial hematologic recovery. However, more research is needed to fully understand the outcomes of this treatment approach. [Extracted from the article]